<div id="readability-page-1">01:56 PM EST, 12/16/2025 (MT Newswires) -- Quipt Home Medical ( QIPT ) price target has been cut to C$5.10, from C$6.70 with a sell rating (previously buy), at Stifel Canada,Stifel noted Quipt is being acquired by private equity managers Kingswood Capital and Forager Capital for US$260 million (US$3.65/sh), representing a 40% premium to the Dec. 12 close price (US$2.61) and 54% to the 30-day VWAP, writes analyst Justin Keywood.It also noted Forager has a 9.7% stake in Quipt and has engaged with the board three times since January, soliciting offers ranging from US$3.10-US$3.90/share. The consideration is &#34;fair&#34;, given the business is sub-scale with a current DOJ billing investigation, as certain other industry headwinds persist, adds Keywood.&#34;Although, a superior bid could emerge with only a US$250k break-fee, we believe the long duration M&amp;A process has been robust as other undervalued healthcare opportunities exist within our coverage and better use of capital.&#34;Price: 4.81, Change: +0.16, Percent Change: +3.44 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

QIPT

Stifel Canada has cut Quipt Home Medical's price target to C$5.10 from C$6.70, following its acquisition by Kingswood Capital and Forager Capital for US$260 million. The acquisition price represents a 40% premium to the Dec. 12 close price. Analyst Justin Keywood notes the acquisition is fair despite industry headwinds and a DOJ investigation. A superior bid could emerge, but the M&A process is considered robust.

Quipt Home Medical Price Target Cut to $5.10 at Stifel Canada After Acquisition Announcement